December 9 2023
FNAIT Natural History Study to Inform Frequency of FNAIT Risk in a Broad and Diverse Population of Pregnant Women.
Study Designed to Provide a Contemporary Control Dataset to Support a Future Registrational Trial in Pregnant Wome.
The study is presently being conducted in the United States and across multiple European countries including Germany, Netherlands, Norway, Sweden and the United Kingdom. Expectant mothers are screened at gestational weeks 10 to 14, enabling early identification and follow-up of
women at higher risk of alloimmunization. Rallybio expects to screen up to 30,000 expectant mothers in the natural history study, with an estimated 7,600 women screened by the end of 2023.
